Hansa Biopharma AB Share Price Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.73 SEK | -76.28% | -5.78% | -38.73% |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
04-18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.5M 1.76B | Sales 2025 * | 343M 32.23M 2.53B | Capitalization | 2.59B 243M 19.09B |
---|---|---|---|---|---|
Net income 2024 * | -735M -69.12M -5.42B | Net income 2025 * | -712M -66.96M -5.25B | EV / Sales 2024 * | 12.8 x |
Net Debt 2024 * | 474M 44.58M 3.5B | Net Debt 2025 * | 733M 68.97M 5.41B | EV / Sales 2025 * | 9.7 x |
P/E ratio 2024 * |
-3.56
x | P/E ratio 2025 * |
-4.22
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 19/03/18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 28/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 28/05/18 | |
Peter Nicklin
CHM | Chairman | 61 | 29/06/22 |
Mats Blom
BRD | Director/Board Member | 59 | 21/05/19 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.53% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |